SciSight Ecosystem
WoS SCIE Q2Scopus Q1SCImago #2,820CAS 3区Gold OA

Translational Oncology

Abbreviation (ISO):TRANSL. ONCOL
Country: United States•WoS SCIE Quartile: Q2•Scopus SJR: 1.383•SCImago Rank: #2,820•Identifier (ISSN):1944-7124(Print)/1936-5233(Online)•Articles / Year: 351•Estimated Publication Fee (APC): $3,470 USD
Clarivate IF (2026)Q2
4.9
↑ +0.8

Leading citation impact metric from Clarivate Journal Citation Reports

JCR Release Date: 2026-06-17
H-Index (2021)
39

39 papers with at least that number of citations each

WoS: SCIE / JCRQ2
Self-Citation Rate2.2%
Safe Level (< 15%)Warning Level (> 20%)
Self-citation below 15% indicates strong scholarly independence.
Volume & Open AccessGold OA
351articles/year
100% Gold OA•97.38% Original Research

State Council for Professorship (HĐGSNN) Scoring

Quyết định số 26/QĐ-HĐGSNN ngày 11/7/2025 (Mục quốc tế)

1.75pts
Latest Max Score
Estimated (Dec 26)
Scoring Basis: WoS Q2 có IF ≥ 2.0(IF: 4.9)

HĐGSNN Score History

By article publication year
YearMax ScoreEvaluation DetailsSource
20261.75đ
WoS Q2 có IF ≥ 2.0(IF: 4.9)
🔵 Computed
20251.75đ
WoS Q2 có IF ≥ 2.0(IF: 4.1)
🔵 Computed
20231.75đ
WoS Q2 có IF ≥ 2.0(IF: 5)
🔵 Computed
20211.75đ
WoS Q2 có IF ≥ 2.0(IF: 4.243)
🔵 Computed

Note: Domestic journal scores are officially collected from annual HĐGSNN decisions across councils. International journal scores are dynamically computed according to Decision 26/QĐ-HĐGSNN based on quartile and citation metrics in the publication year.

Aims & Scope

Translational Oncology publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of oncology patients. Translational Oncology will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. Peer reviewed manuscript types include Original Reports, Reviews and Editorials.

Topics Covered (Recognized by AI)
Medicine97.5%Biology96.3%Genetics94%Internal medicine91.6%Chemistry74.9%Cancer72.3%Biochemistry71.4%Cancer research66.2%Pathology54.5%Gene48%Immunology39.8%Oncology39.2%Surgery34.8%Cell biology27%Radiology23.5%Apoptosis21.7%Physics21.1%
Primary Research Areas

SCImago & Scopus Journal Intelligence

Global SCImago ranking, SJR prestige index, Scopus coverage, and societal policy impact

Rank #2,820Scopus Q1SCImago Profile
Scopus Coverage:2008-2026
Scopus Broad Areas:Biochemistry, Genetics and Molecular BiologyMedicine
Scopus Citation Rank (SJR)Q1
1.383

Weighted prestige citation metric per document indexed in the Scopus database.

Tứ phân vị: Scopus Q1
Scopus H-Index (2025)
84

Measures cumulative publication volume and citation impact.

Scopus Database Indexed (2025)
Citations / Doc (2 years)
5.03

Average citations received per document published in the 2-year window.

2-Year Citation Window
Estimated Publication Fee (APC)
$3,470 USD

Estimated Article Processing Charge for Open Access publication.

Chi phí ước tính / bài báo

Scopus 3-Year Publication & Citation Window

3-Year Citations4,301
3-Year Documents876
Citable Documents865

Aggregated from Scopus database across the 3-year SJR evaluation window.

Societal Impact & Inclusivity (SCImago)

Policy Citations (Overton)0

Citations in government and international policy documents

Female Author Rate44.9%

Percentage of female authors published in the journal

Real-world societal policy reach and author gender diversity tracked by SCImago.

Scopus Subject Categories

OncologyQ1
Cancer ResearchQ2

Chinese Academy of Sciences (CAS) Classification

Major / minor zone classification and CAS Early Warning List history

Major Category (Broad Field):
3区 (Zone 3)Medicine
Minor Category (Specific Field):
3区ONCOLOGY
CAS Early Warning List History:
Updated annually: 2020 – 2024
2020
Not warned
2021
Not warned
2022
Not warned
2023
Not warned
2024
Not warned

Publishing & Editorial Information

Detailed publisher, peer-review turnaround, and publication cycle specifications

Publisher Review Speed
Updating
Average time to first editorial decision
Online Publication Speed
Updating
Time from acceptance to online publication
Official Acceptance Rate
Updating
Manuscript acceptance rate confirmed by the publisher
Open Access Model
Gold OA
OA publishing option or traditional subscription
Publisher
Neoplasia Press
Publication Language
English
Frequency
Periodic
Editorial Address
STE 800, 230 PARK AVE, NEW YORK, USA, NY, 10169
Indexing & Databases
SCIEScopusDOAJPubMed

WoS Categories & Quartiles

Detailed JCR / JCI category rankings and quartile breakdown from Clarivate

Clarivate JCR & JCI
CategoryIndexRankQuartile
ONCOLOGY
JCRSCIE
89/333Q2
ONCOLOGY
JCISCIE
88/333Q2

Annual Historical Statistics & Publications

Track annual publication volume, total citations, and Impact Factor evolution

12 year
YearImpact FactorArticles / YearTotal Citations
2026—363129
20254.13781,200
2024—3963,417
202352413,539
2022—2724,830
20214.2433219,830
2020—2778,656
2019—1644,915
2018—1966,647
2017—1274,280
2016—933,620
2015—682,161
Academic Metric Intelligence

Journal Metrics & Citation Visualizations

Impact Factor Trend (2018–2024)

Clarivate IF trend for Translational Oncology

WoS Q2
23562021202320254.10
Annual Impact Factor Metric
2025:4.1

Total Cites vs Self-Cites

Evaluation of scholarly independence and citation reach

Total citations steady growth
Self-citation: 2.2%

Citations per Document

Citation metric windows across 2, 3, and 4 years

Cites / Doc (4 years)Cites / Doc (3 years)Cites / Doc (2 years)

Similar Journals in Discipline

Journals in the same research field with comparable impact metrics

Record UUID: 662a58fc-1497-4b63-855f-66e6d2402908
Database Updated: 2026-10-01